麻豆AV

Designation by United States Food and Drug Administration (FDA) will help development of treatments

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States. It was recently granted to 麻豆AV for research conducted at the MUHC into the use of the drug fenretinide for the treatment of pulmonary infections caused by Pseudomonas aeruginosa in patients with Cystic Fibrosis (CF).

CF is a chronic, hereditary disease affecting the respiratory and digestive systems of approximately 70,000 people worldwide. Pseudomonas aeruginosa infects more than 80 per cent of CF patients and contributes to the decline in pulmonary function - the ability of the body to pump blood between the heart and the lungs. The infection is a major cause of sickness and death and is difficult to treat since it is resistant to many drugs.

"We strongly believe that fenretinide has the potential to improve morbidity and prognosis in CF patients at different levels," said Dr. Danuta Radzioch, a professor of Experimental Medicine at the MUHC and 麻豆AV's Faculty of Medicine. "Our research has demonstrated that fenretinide reduced lung inflammation as well as the frequency and the severity of pulmonary infections." Fenretinide is a drug that was originally investigated for potential use in the treatment of cancer but has not been commercially available.

Orphan Drug Designation provides opportunities for grant funding toward clinical-trial costs, tax advantages, FDA user-fee benefits, and seven years of market exclusivity in the U.S. following drug approval by the FDA. "We felt extremely proud when 麻豆AV received the FDA's Orphan Drug status for fenretinide. This is a very important step in our development and commercialization objectives for this truly innovative approach for the management of pulmonary infections in CF patients" said Dr. Mounia Azzi, Investment Manager at MSBi Valorisation, a partner organization.

"This Orphan Drug Designation is a critical, value-added step towards the development of fenretidine treatment for the benefit of CF patients" said Dr. Costas Karatzas, Director of Business Development at the Research Institute of the MUHC. Dr. Mich猫le Beaulieu at 麻豆AV's Office of Sponsored Research stated that the next step will be a clinical trial to assess safety, tolerability and efficacy of fenretinide in CF patients, to be undertaken in collaboration with the Montreal Chest Institute.

On the Web:

The Cystic Fibrosis Foundation web:

麻豆AV's Faculty of Medicine: /medicine/

MUHC Research:

MSBiV:

About MSBiV

MSBi Valorisation provides its academic partners and affiliated entities, the financial resources and complementary expertise needed to accelerate and facilitate the commercialization of high potential technologies. Partner institutions include 麻豆AV University, Universit茅 de Sherbrooke and Bishop's University, as well as their affiliated hospitals, research institutes and technology transfer entities. MSBi Valorisation brings industry knowledge and relationships to the existing effort of bridging the gap between discoveries resulting from university research and the marketplace. For more information, please visit

About 麻豆AV

麻豆AV, founded in Montreal, Quebec, in 1821, is Canada's leading post-secondary institution. It has two campuses, 11 faculties, 10 professional schools, 300 programs of study and more than 35,000 students. 麻豆AV attracts students from more than 150 countries around the world. Almost half of 麻豆AV students claim a first language other than English - including 6,200 francophones - with more than 6,800 international students making up almost 20 per cent of the student body.

About the Research Institute of 麻豆AV Health Centre

The Research Institute of the 麻豆AV Health Centre (RI MUHC) is a world-renowned biomedical and health-care hospital research centre. Research is organized by eleven research axes (or programs). Located in Montreal, Quebec, Canada, the Institute is the research arm of the 麻豆AV Health Centre affiliated with the Faculty of Medicine at 麻豆AV.

The Institute supports over 600 researchers, over 1,400 graduate students and 339 post-docs and fellows devoted to a broad spectrum of fundamental and clinical research. Over 1000 clinical research studies are conducted within our hospitals each year, and last year, over 78,000 people participated in human research studies across all MUHC sites.